Technical Analysis for CBAY - CymaBay Therapeutics Inc.

Grade Last Price % Change Price Change
grade F 5.63 1.08% 0.06
CBAY closed up 1.08 percent on Friday, September 20, 2019, on 2.34 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical CBAY trend table...

Date Alert Name Type % Chg
Bullish Engulfing Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Stochastic Reached Oversold Weakness 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Signal Line Cross Bearish 0.36%
20 DMA Resistance Bearish -3.92%
Narrow Range Bar Range Contraction -4.09%
NR7 Range Contraction -4.09%
50 DMA Resistance Bearish -2.09%
Fell Below 20 DMA Bearish -2.09%

Older signals for CBAY ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Cymabay Therapeutics, Inc. focuses on developing therapies to treat metabolic diseases. Its lead product candidate is Arhalofenate, which completed five Phase II clinical trials for the treatment of gout. The company's product candidate also includes MBX-8025, a selective agonist that is in a Phase II clinical trial in patients with mixed dyslipidemia; and MBX-2982, an oral, G-protein coupled receptor agonist to treat type II diabetes. Cymabay Therapeutics, Inc. has a development and license agreements with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of T2DM and other disorders; and a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products. The company was formerly known as Metabolex, Inc. Cymabay Therapeutics, Inc. was incorporated in 1988 and is based in Newark, California.
Medicine Chemistry Disorders Health Care Therapeutic Products Regulus Therapeutics Metabolic Diseases Ii Diabetes Gout
Is CBAY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 14.0
52 Week Low 4.82
Average Volume 540,105
200-Day Moving Average 9.3005
50-Day Moving Average 5.9942
20-Day Moving Average 5.848
10-Day Moving Average 5.897
Average True Range 0.2992
ADX 29.12
+DI 15.5611
-DI 25.8596
Chandelier Exit (Long, 3 ATRs ) 5.6624
Chandelier Exit (Short, 3 ATRs ) 6.3176
Upper Bollinger Band 6.3029
Lower Bollinger Band 5.3931
Percent B (%b) 0.26
BandWidth 15.557456
MACD Line -0.0981
MACD Signal Line -0.0765
MACD Histogram -0.0216
Fundamentals Value
Market Cap 246.34 Million
Num Shares 43.8 Million
EPS -1.07
Price-to-Earnings (P/E) Ratio -5.26
Price-to-Sales 82.44
Price-to-Book 122.03
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.98
Resistance 3 (R3) 5.94 5.80 5.92
Resistance 2 (R2) 5.80 5.71 5.81 5.90
Resistance 1 (R1) 5.71 5.65 5.76 5.75 5.88
Pivot Point 5.57 5.57 5.59 5.58 5.57
Support 1 (S1) 5.48 5.48 5.53 5.52 5.38
Support 2 (S2) 5.34 5.42 5.35 5.36
Support 3 (S3) 5.25 5.34 5.34
Support 4 (S4) 5.29